There are few studies which attest the efficacy of acupuncture on treatment of sleep disturbs in Parkinson disease.
Introduction
Parkinson's disease (PD) is a neurodegenerative disorder with a high prevalence in older people, affecting 1 in 1000 people aged >60 years. Although it has been widely accepted that is has a relationship with dopaminergic neuron death, its etiology remains unknown [1, 2] . Sleep disturbance is often a nonmotor symptom in PD, which includes excessive daytime sleepiness and insomnia [3e6] . Such sleep disturbance occurs as part of the disease course of the evolution of PD, and as a side effect of antiparkinsonian medication [7, 8] .
Acupuncture is a method in Traditional Chinese Medicine that was developed in the 1 st century BCE [9, 10] . With regards to PD, some studies have suggested promising results, such as relief of a wide range of symptoms and a reduction in adverse drug effects [11, 12] . Acupuncture has been shown to improve scoring on the Parkinson's Disease Sleep Scale (PDSS) [13] . This result may reflect neuromodulation by substances like g-aminobutyric acid, melatonin, and b-endorphins [14] .
The present study evaluated the effects of acupuncture on sleep disturbance in patients participating in the ProParkinson Program at the Clinical Hospital, Federal University of Pernambuco, Brazil.
Materials and methods

Ethics statement
This was a randomized clinical trial conducted according to the CONSORT 2010 checklist. All patients signed an informed consent form, and the study was approved by the Ethics Committee for Research with Humans at the Center of Health Sciences of Federal University of Pernambuco (Protocol CAAE: 49662915.4.0000.5208). This trial was registered at ClinicalTrials.gov NCT: 02731677. (5) a stable dose of antiparkinsonian medication for ! 2 months. We excluded patients who had another neurological condition or who had received physiotherapy. The patients were enumerated and allocated to experimental or control groups according a simple raffle.
Participants
The Pro-Parkinson Program promotes multidisciplinary assistance for patients with PD. It also offers educational activities for patients and their caregivers. Currently, the program receives an average of 250 patients annually, and comprises of professors and undergraduate and postgraduate students in medicine, physiotherapy, odontology, psychology, speech therapy, and occupational therapy, as well as a support team.
Clinical assessment
All patients were clinically evaluated prior to starting the study with the following instruments: MMSE, HY scale, and PDSS, and after eight sessions, only PDSS was applied.
HY scale
The HY scale was developed by Hoehn and Yahr [16] . The original version consists of five stages that evaluate the severity of PD by analyzing global signals and symptoms, which classifies individuals according to their incapacity. Stage I: patients present with unilateral symptoms (tremor, stiffness, and bradykinesia) but can have autonomy. Stage II: bilateral symptoms together with abnormal speech, bent posture, and the well-known "en-bloc gait". Stage III: addition of characteristic postural instability; until this stage, autonomy can be preserved. Stage IV: patients are dependent on caregivers. Stage V: patients are restricted to bed or a wheelchair.
MMSE
MMSE is a useful tool for screening for cognitive disturbance because of its ease of application and that fact that it only requires 5e10 minutes. It comprises of 11 items that can accumulate a total score of 30 points. The first part of the test evaluates memory and executive function (attention and concentration), and the second part evaluates cortical function. The cutoff is according to academic achievement: analphabetism or low academic achievement, 18 points; ! 8 years of schooling, 26 points [17].
PDSS
PDSS is a visual analog and self-administered scale comprising 15 items that address the following domains: (1) overall quality of sleep; (2) sleep onset and maintenance insomnia; (3) nocturnal restlessness; (4) nocturnal psychosis; (5) nocturia; (6) nocturnal motor symptoms; (7) sleep refreshment; and (8) daytime dozing. It is administered during the ON phase, which means under antiparkinsonian drug action. The severity of symptoms is registered by the
